Has There Been A Sea Change In Trial Diversity Efforts?

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

PhRMA partnered with Deloitte to produce a report that included a survey of 31 member companies indicating that most had made significant investments in improving clinical trial diversity.

PhRMA and Deloitte partnered to conduct a survey on companies' clinical research diversity efforts • Source: Shutterstock

Companies across the biopharmaceutical industry have been busy investing in a variety of strategies to improve clinical trial diversity, ranging from partnerships with diverse community organizations to greater adoption of decentralized trials. But a macro-level assessment reveals varying degrees of progress, with some players making enormous strides and others that still have a lot of work ahead of them.

A November report from the Pharmaceutical Research and Manufacturers of America (PhRMA) and Deloitte, based on interviews with 31 member...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Diversity & Inclusion

Publisher’s Spotlight: The Winners Of The 2024 Citeline Awards

 
• By Mary Jo Laffler

Congratulations to the winners of the 2024 Citeline Awards, held 8 May in Boston. 

Publisher’s Spotlight: The Citeline Awards Are Open For Entries!

 
• By Mary Jo Laffler

Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees. 

Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

 
• By Eleanor Malone

Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.

Scrip Asks…What Does 2024 Hold For Biopharma? Part 1: Business Strategy And Leadership

 
• By Eleanor Malone

Global crises and a tough funding environment mean biopharma leadership teams need to work hard to survive, let alone thrive. Industry executives shared their predictions and advice on strategy for 2024.

More from ESG

Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

 
• By Eleanor Malone

Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.

Scrip Asks…What Does 2024 Hold For Biopharma? Part 1: Business Strategy And Leadership

 
• By Eleanor Malone

Global crises and a tough funding environment mean biopharma leadership teams need to work hard to survive, let alone thrive. Industry executives shared their predictions and advice on strategy for 2024.

Profile: MSD India Chief On DEI Values, Keytruda And 'Drinking From The Firehose'

 
• By Anju Ghangurde

MSD India managing director Rehan Khan shares with Scrip glimpses of his life and professional journey, including diversity, equity and inclusion values imbibed in his childhood, co-founding an early-stage venture fund, widening access to Keytruda to roughly “six times more patients” in the country and initiatives around HPV vaccination.